Fishman Jay A Ltd. MI Has $21.42 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Fishman Jay A Ltd. MI lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 3.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 596,145 shares of the biopharmaceutical company’s stock after selling 23,220 shares during the period. Pfizer makes up approximately 4.0% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 8th largest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $21,419,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of PFE. Morgan Stanley raised its position in shares of Pfizer by 2.4% in the second quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after buying an additional 1,071,897 shares in the last quarter. Fisher Asset Management LLC raised its position in Pfizer by 2.6% during the third quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock valued at $1,627,320,000 after purchasing an additional 1,158,147 shares in the last quarter. Nuveen Asset Management LLC raised its position in Pfizer by 2,240.5% during the second quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after purchasing an additional 34,544,423 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Pfizer by 2.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock valued at $1,557,306,000 after purchasing an additional 868,839 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in Pfizer by 5.3% during the second quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after purchasing an additional 1,159,857 shares in the last quarter. Institutional investors own 71.52% of the company’s stock.

Shares of NYSE PFE traded up $0.14 during midday trading on Friday, reaching $37.05. 24,924,227 shares of the company were exchanged, compared to its average volume of 23,366,957. The stock’s 50-day moving average price is $36.62 and its 200-day moving average price is $39.26. The stock has a market cap of $207.30 billion, a P/E ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a one year low of $33.97 and a one year high of $46.47. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company’s revenue was down 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.78 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. Pfizer’s payout ratio is presently 48.00%.

In related news, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at approximately $104,160. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Several research analysts have commented on the stock. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research report on Wednesday, August 28th. Credit Suisse Group restated a “hold” rating and set a $41.30 price objective on shares of Pfizer in a research report on Wednesday. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $44.02.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply